SecBot SecBot
6-K ·Filed Nov 16, 2026
DA

DAVI

DAVION HEALTHCARE PLC
NEUTRAL
Impact 4/10
Horizonmonths Processed5d 20h ago SEC0001683168-26-008791
Notable filing: 6-K
Actionable Insight • Neutral

Monitor for definitive agreement execution by December 31, 2026 target date and regulatory approvals. The $1M share component at $13.00 per share implies modest dilution (~76,923 shares). Completion risk is high given the preliminary nature of the agreement.

DirectionNeutral
Confidencemedium
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$1.02
T+0 close · Nov 16, 2026 · via day close
Latest settled
+0.98%
T+1 · $1.03
Vs SPY
+2.00%
α at T+1
Next horizon
T+5
in 23h
  1. T+0 · Nov 16 $1.02entry
  2. T+1 · 5d ago +0.98%α +2.00% · $1.03
  3. T+4 · todayOpen
  4. T+5 · in 23h Pending
  5. T+20 · in 23d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Davion Healthcare announced a proposed acquisition of 14 Independence Care homecare businesses across 10 US states for up to $10 million in cash, shares and earnouts. The target businesses generated approximately $17 million in combined 2025 revenue. The transaction is subject to due diligence, definitive agreements and regulatory approvals, with no guarantee of completion.

Key Facts

  • Signed agreement to acquire 14 Independence Care homecare businesses across 10 US states
  • Total consideration up to $10 million: $4.5M cash at definitive agreement closing, $3.5M cash at milestone, $1M in Davion shares (~76,923 shares at $13.00 reference price), up to $1M cash earnouts
  • Target businesses generated combined revenues of approximately $17 million in 2025
  • Transaction is cash-free, debt-free; subject to due diligence, definitive agreements and regulatory approvals
  • Davion market cap is approximately $30 million; the $10M consideration represents about 33% of market cap

Financial Impact

Up to $10 million total consideration, representing approximately 33% of Davion's $30M market cap. Target revenues of ~$17M would more than double Davion's current revenue base if completed.

revenuedilutioncash

Risk Factors

  • Transaction may not close due to failed due diligence, inability to reach definitive agreements, or regulatory hurdles
  • Consideration includes $8M in cash, which is material relative to Davion's $30M market cap and may require financing
  • Earnout payments depend on future revenue and EBITDA performance targets for 2027-2028
  • document contains text addressed to automated readers

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001683168-26-008791
Document: davion_6k.htm0001683168-26-008791
Document: 0001683168-26-008791-index-headers.html0001683168-26-008791
Document: 0001683168-26-008791-index.html0001683168-26-008791
Document: 0001683168-26-008791.txt0001683168-26-008791
Earnings Context (Synthetic; results releases only)0001683168-26-008791

US Market Status

Market Closed · Opens Mon (25h 57m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 16, 2026